Therefore, the US FDA, on December 6, 2018, approved the ABCP as a first-line immunotherapy in patients with non-squamous NSCLC not harboring EGFR/ALK mutations, independent of the expression levels of the PD-L1. This evidence concerns the gene ALK and non-small cell lung carcinoma.